We’ve been hearing and writing about a substantial amount of news and information on various immuno-oncology developments over the last year, especially in metastatic melanoma and lung cancer, but despite renal cell cancer (RCC) being a proven immune-sensitive disease with known PD-L1 expression, it seems to be the poor cousin to the other two tumour types given the lag in data and relative media attention.
There’s actually quite a lot going on in this disease though, from biomarker work to phase I to III trials that are either ongoing or just started accruing.
We should be hearing much more about the role of anti-PD–1 and PD-L1 antibodies in RCC over the next couple of years, including data from some large randomised controlled trials, but what’s the current state of play?
With that in mind, I was deligted to catch up with David McDermott’s (DFCI) in-depth presentation at ASCO GU in San Francisco over the weekend. It’s always unfortunate when an interesting talk is left for the final presentation on the last day of a conference, as only a few diehards will be there to catch it! It was a well thought out discussion though and he covered a lot of interesting ground in this space.
ipilimumab, nivolumab, MK–3475, MPDL3280A, LAG–3, TIM–3, PD-L2, IL–2, sunitinib, everolimus, bevacizumab
BMS, Roche/Genentech, Merck, GSK, Novartis, Pfizer
You can sign in or sign up below to read my analysis of the state of play of immuno-oncology in the kidney cancer market.